Latest Breaking News On - Deric dube - Page 1 : comparemela.com

Travere Therapeutics, Inc (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript

Travere Therapeutics, Inc (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

United statesJula inrigMaury raycroftEric dubeyWilliam blairAnupam ramaAnne crotteauTyler van burenCarter gouldDeric dubeJoseph schwartzTim lugoChris clineJason zemanskyPeter heermaMirum pharmaceuticals

Travere Therapeutics Reports First Quarter 2024 Financial Results

FDA grants Priority Review for sNDA to convert FILSPARI® from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511.

United statesRenalys pharmaDeric dubeDrug administrationProgram updatesNational symposiumAmerican nephrology nurses associationEuropean commissionExchange commissionLigand pharmaceuticalsDevices agencyTravere therapeutics incSociety for inherited metabolic disordersRenalys pharma incEuropean unionGenetic metabolic dieticians international

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New zealandDeric dubeThomas hutterEmmanuelle lecomte brissetVifor internationalHead of global regulatory affairsEuropean medicines agencyTravere therapeutics incFresenius medical careCommittee for medicinal products human useUniversity hospitalEuropean commissionEuropean unionIga nephropathyTravere therapeuticsSenior professor

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

First non-immunosuppressive therapy for the treatment of IgA nephropathy approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful.

New zealandEmmanuelle lecomte brissetThomas hutterDeric dubeUniversity hospitalEuropean commissionTravere therapeutics incFresenius medical careExchange commissionEuropean unionCommittee for medicinal products human useClinical immunologyMedicinal productsHuman useTravere therapeuticsIga nephropathy

Travere Therapeutics (TVTX) and CSL Vifor Announce EU Approval of FILSPARI

Travere Therapeutics (TVTX) and CSL Vifor Announce EU Approval of FILSPARI
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New zealandEmmanuelle lecomte brissetDeric dubeCommittee for medicinal products human useEuropean unionTravere therapeutics incEuropean commissionUniversity hospitalTravere therapeuticsClinical immunologyMedicinal productsHuman use